



Medicines & Healthcare products
Regulatory Agency

10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom
[gov.uk/mhra](https://www.gov.uk/mhra)

[REDACTED]
[REDACTED]

20/03/2024

Dear [REDACTED],

RE: FOI 24/181

Thank you for your email dated 22 February 2024 where you requested:

Data on yellow card reports for the one-year-old jabs in particular the MMR.

I can confirm the MHRA does hold this information. The information provided in this response is as per the current [UK routine immunisation schedule](#) (1 September 2023). It is important to note that these vaccines are also given at various ages and as such the information provided to you within this response will include Yellow Cards reported for all patients regardless of age. If you are interested in receiving information specifically in 1-year-old patients, we can provide this to you in a new request. It is important to bear in mind however that patient age is not a mandatory field on a Yellow Card report and as such isn't always provided.

The MHRA continuously monitors the safety of vaccines through a variety of pharmacovigilance processes including the Yellow Card scheme. As part of our signal detection processes all adverse reaction reports received by the Yellow Card scheme are individually assessed and cumulative information reviewed at regular intervals. If appropriate, regulatory action would be taken if any serious risks were confirmed.

As these data do not necessarily refer to proven side effects, you should refer to the product information which can be found here: <https://www.medicines.org.uk/emc/> for details on the possible side effects of these vaccines.

Number of UK spontaneous suspected adverse reaction reports associated with vaccines routinely administered at one years old* up to and including 06/03/2024

Vaccine	Total number of reports
Measles, mumps and rubella (MMR)	8129
Pneumococcal Conjugate Vaccine (PCV)	3048
Hib and MenC	718
MenB	3077

*As per the current [UK routine immunisation schedule](#) (1 September 2023).

Please note that the number of reports in the table above cannot be summed to give a total number of reports for all vaccines, as some reports will contain more than one vaccine.

Further to your request, please find attached Vaccine Analysis Prints (VAPs) which contain information on all the UK spontaneous suspected adverse reaction reports received through the Yellow Card scheme up to and including 06/03/2024 for each vaccine requested. The attached guidance sheet provides you with further information on how to interpret the print.

When considering the spontaneous data within this response, it is important to be aware of the following points:

- A reported reaction does not necessarily mean it has been caused by the vaccine, only that the reporter had a suspicion it may have. Each year, millions of doses of routine vaccinations are given in the UK alone, and when any vaccine is administered to large numbers of people, some recipients will inevitably experience illness following vaccination. The fact that symptoms occur after use of a vaccine or medicine, and are reported via the Yellow Card scheme, does not in itself mean that they are proven to have been caused by it. Underlying or concurrent illnesses may be responsible and such events can also be coincidental.
- It is also important to note that the number of reports received via the Yellow Card scheme does not directly equate to the number of people who suffer adverse reactions and therefore cannot be used to determine the incidence of a reaction or compare the safety profile of different vaccines. ADR reporting rates are influenced by the seriousness of ADRs, their ease of recognition, the extent of use of a particular medicine, and may be stimulated by promotion and publicity about a drug. Reporting tends to be highest for newly introduced medicines during the first one to two years on the market and then falls over time.

We hope the information provided is helpful, but if you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of this response; and can be addressed to this email address.

Yours sincerely,

FOI Team
Safety and Surveillance
Medicines and Healthcare products Regulatory Agency

The MHRA information supplied in response to your request is subject to Crown copyright. The FOIA only entitles you to access to MHRA information.

For information on the reproduction or re-use of MHRA information, please visit

<https://www.gov.uk/government/publications/reproduce-or-re-use-mhra-information/reproduce-or-re-use-mhra-information>

If you have a query about this email, please contact us. If you are unhappy with our decision, you may ask for it to be reviewed. That review will be undertaken by a senior member of the Agency who has not previously been involved in your request. If you wish to pursue that option please write to the Communications Directorate, Medicines and Healthcare products Regulatory Agency, (via this email address). After that, if you remain dissatisfied, you may ask the Information Commissioner at: Information Commissioner's Office Wycliffe House Water Lane Wilmslow Cheshire SK9 5AF.